Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).
Douglas B JohnsonFengmin ZhaoMarcus NoelGregory J RielyEdith P MitchellJohn J WrightHelen X ChenRobert C GrayShuli LiLisa Meier McShaneLawrence V RubinsteinDavid PattonP Mickey WilliamsStanly R HamiltonBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerKeith T FlahertyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Trametinib did not show promising clinical activity in patients with tumors harboring non-V600 BRAF mutations, and the subprotocol did not meet its primary endpoint.
Keyphrases